Skip to main content

Table 3 Comparison of study data with prevalence in median age group according to current data from Germany

From: Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients

  Our data Prevalence in median age group
Sex (m:f) 117:142; 55% female prevalence for PG: 0.3-1.0/100.000
(Germany: 1000:1040; 51% female)
Age (mean) 21-94 years (57.3 years)
(Germany, 2010: 44.3 years)
Associated inflammatory disorders
Arthrosis, non rheumatoid arthritis 17 (6.6%) female (45–65 years): 33%
male: (45–65 years): 25%
Rheumatoid arthritis 24 (9.3%) female (45–64 years): 8.6%
male (45–64 years): 5%
overall: 0.5-0.8%
Chronic inflammatory bowel disease Overall: 24 (9.3%) Crohn’s disease:
Crohn’s disease: 120-200/100.000
7 (2.7%) Ulcerative colitis:
Ulcerative colitis: 17 (6.6%) 160-250/100.000
Endocrine disorders
Thyroid disease 29 (11.2%) overall: 5.5%
female: 8.9%
male: 1.8%
Diabetes mellitus 66 (25.5%) international overall (20–79 years): 12%
German overall: 8.9%
Neoplasia 32 (12.4%) overall: 5-yr.-prevalence: 1.6%
10-yr.-prevalence: 2.4%
Solid neoplasms (overall) 22 (8.5%)  
Breast cancer 6 (2.3%) female (50–59 years): 1-year-prevalence: 0.2%
Lung cancer 3 (1.6%) female: 50–59 years: 1-year-prevalence: 0.04%
male: 50–59 years: 1-year-prevalence: 0.07%
Prostate cancer 3 (1.6%) male overall: 1-year-prevalence: 0.1%
male (60–69 years): 1-year- prevalence: 0.5%
Melanoma 3 (1.6%) female (50–59 years): 1-year.-prevalence: 0.03%
male (50–59 years): 1-year life-prevalence: 0.02%
Hepatocellular carcinoma 2 (0.8%) overall: 7-8/100.000
Ovarian cancer 2 (0.8%) female (50–59 years): 1-year life-prevalence: 0.03%
Colon cancer 1 (0.4%) female (50–59 years): 1-year.-prevalence: 0.1%
male (50–59 years): 1-year-prevalence:
Laryngeal cancer 1 (0.4%) female: 1-year-prevalence: <0.01%
male: 1-year-prevalence: <0.1%
Glioblastoma multiforme 1 (0.4%) n.a.
Hematologic/hematopoetic neoplasia   Leukemia, female:1-year-prevalence: 0.01%
AML 1 (0.4%)  
CML 2 (0.8%) Leukemia, male:
Other 7 (2.8%) 1-year-prevalence: 0.01%